Evaluating the Safety and Pharmacokinetics of VRC07-523LS in the Sera and Mucosae of Healthy, HIV-Uninfected Adult Participants
Study Details
Study Description
Brief Summary
The purpose of this study is to evaluate the safety and pharmacokinetics of a human monoclonal antibody (VRC07-523LS) in the sera and mucosae of healthy, HIV-uninfected adults.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
This study will evaluate the safety and pharmacokinetics of a human monoclonal antibody (VRC07-523LS) in the sera and mucosae of healthy, HIV-uninfected adults.
Participants will be randomly assigned to one of two groups. Participants in Group 1 will receive 10 mg/kg of VRC07-523LS at Weeks 0, 16, and 32. Participants in Group 2 will receive 30 mg/kg of VRC07-523LS at Weeks 0, 16, and 32.
Study visits will occur at Weeks 0, 2, 16, 18, 32, 34, and 48. Visits may include physical examinations; blood and urine collection; rectal, cervicovaginal, and seminal secretion collection; cervical, rectal, and vaginal biopsy collection; HIV testing; risk reduction counseling; and questionnaires. Study staff will contact participants at Week 50 for follow-up safety monitoring.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| No Intervention: Pre-treatment Biopsy collected but was not randomized to any treatment group |
|
| Experimental: Group 1: VRC07-523LS Participants will receive 10 mg/kg of VRC07-523LS at Weeks 0, 16, and 32. |
Biological: VRC07-523LS
Administered by intravenous (IV) infusion
Other Names:
|
| Experimental: Group 2: VRC07-523LS Participants will receive 30 mg/kg of VRC07-523LS at Weeks 0, 16, and 32. |
Biological: VRC07-523LS
Administered by intravenous (IV) infusion
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Number of Participants Reporting Local Reactogenicity Signs and Symptoms [Measured through 3 days after each infusion at weeks 0, 16 and 32]
Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1, July 2017. The maximum grade observed for each symptom over the time frame is presented.
- Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms [Measured through 3 days after each infusion at weeks 0, 16 and 32]
Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1, July 2017. The maximum grade observed for each symptom over the time frame is presented
- Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT) in U/L [Measured during screening, visit 4(day 14), 6 (day 126) and 8 (day 238)]
For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population.
- Chemistry and Hematology Laboratory Measures- Hemoglobin and Creatinine (g/dl) [Measured during screening, Day 14, 126, 238]
For each local laboratory measure-Hemoglobin and Creatinine (g/dl), summary statistics were presented by treatment group and time point for the overall population.
- Chemistry and Hematology Laboratory Measures- Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) [Measured during screening, Day 14, 126, 238]
For each local laboratory measure lymphocyte count, neutrophil count, platelets, white blood cells (WBC) in 1000/ cubic mm summary statistics were presented by treatment group and time point
- Chemistry and Hematology Laboratory Measures [Measured during screening, Day 14, 126, 238]
Counts of lab grade >1 for ALT, creatine, hemoglobin, lymphocyte count, neutrophil, platelets, white blood cells
- Number of Participants Reporting Adverse Events (AEs) [Enrollment through week 48]
Participants Max severity reported per participant over visit.
- Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation [Enrollment through last scheduled dose at week 32]
The number (percentage) of participants with early discontinuation of vaccinations and reason for discontinuation was summarized by arm
Eligibility Criteria
Criteria
Inclusion Criteria:
General and Demographic Criteria
-
Age of 18 to 50 years
-
Access to a participating HIV Vaccine Trials Network (HVTN) clinical research site (CRS) and willingness to be followed for the planned duration of the study
-
Ability and willingness to provide informed consent
-
Assessment of understanding: volunteer demonstrates understanding of this study and completes a questionnaire prior to first study product administration with verbal demonstration of understanding of all questionnaire items answered incorrectly
-
Agrees not to enroll in another study of an investigational research agent until completion of the last required protocol clinic visit
-
Good general health as shown by medical history, physical exam, and screening laboratory tests
HIV-Related Criteria:
-
Willingness to receive HIV test results
-
Willingness to discuss HIV infection risks and amenable to HIV risk reduction counseling.
-
Assessed by the clinic staff as being at "low risk" for HIV infection and committed to maintaining behavior consistent with low risk of HIV exposure through the last required protocol clinic visit. See the study protocol for US Low risk guidelines.
Laboratory Inclusion Values
Hemogram/Complete blood count (CBC)
-
Hemoglobin greater than or equal to 11.0 g/dL for volunteers who were assigned female sex at birth, greater than or equal to 13.0 g/dL for volunteers who were assigned male sex at birth. For transgender participants who have been on hormone therapy for more than 6 consecutive months, determine hemoglobin eligibility based on the gender with which they identify (ie, a transgender female who has been on feminizing hormone therapy for more than 6 consecutive months should be assessed for eligibility using the hemoglobin parameters for persons assigned female sex at birth).
-
White blood cell (WBC) count equal to 2,500 to 12,000 cells/mm^3
-
WBC differential either within institutional normal range or with site physician approval
-
Platelets equal to 125,000 to 550,000/mm^3
Chemistry
- Chemistry panel: Alanine aminotransferase (ALT) less than 1.25 times the institutional upper limit of normal and creatinine less than or equal to institutional upper limits of normal.
Virology
-
Negative HIV-1 and -2 blood test: US volunteers must have a negative US Food and Drug Administration (FDA)-approved enzyme immunoassay (EIA) or chemiluminescent microparticle immunoassay (CMIA).
-
Negative Hepatitis B surface antigen (HBsAg)
-
Negative anti-Hepatitis C virus (anti-HCV) antibodies, or negative HCV polymerase chain reaction (PCR) if the anti-HCV is positive
Urine
-
Normal urine:
-
Negative or trace urine protein
Reproductive Status
-
Volunteers who were assigned female sex at birth: negative serum or urine beta human chorionic gonadotropin (β-HCG) pregnancy test performed prior to biopsy collection and/or study product administration.
-
Reproductive status: A volunteer who was assigned female sex at birth must:
-
Agree to use effective contraception for sexual activity that could lead to pregnancy from at least 21 days prior to enrollment through the last required protocol clinic visit. Effective contraception is defined as using the following methods:
-
Condoms (male or female) with or without a spermicide,
-
Diaphragm or cervical cap with spermicide,
-
Intrauterine device (IUD),
-
Hormonal contraception, or
-
Any other contraceptive method approved by the HVTN 128 Protocol Safety Review Team (PSRT)
-
Successful vasectomy in any partner assigned male sex at birth (considered successful if a volunteer reports that a male partner has [1] documentation of azoospermia by microscopy, or [2] a vasectomy more than 2 years ago with no resultant pregnancy despite sexual activity postvasectomy);
-
Tubal ligation
-
Or be sexually abstinent until at least 4 months following the last study product administration.
-
Volunteers who were assigned female sex at birth must also agree not to seek pregnancy through alternative methods, such as artificial insemination or in vitro fertilization until after the last required protocol clinic visit
Mucosal Specimen Collection
-
Volunteers 21 years of age and older who were assigned female sex at birth: Pap smear (verified by medical records) is required within:
-
the 3 years prior to enrollment with the latest result reported as normal or ASCUS (atypical squamous cells of undetermined significance), OR
-
the 5 years prior to enrollment, with the latest result reported as normal, or ASCUS with no evidence of high risk HPV.
-
If no Pap smear was done within the last 3 years (or within the last 5 years, if high risk HPV testing was performed), the volunteer must be willing to undergo a Pap smear with the result reported (verified by medical records) as normal or ASCUS prior to sample collection.
-
Willing to have mucosal secretions and tissue biopsies collected at several timepoints
-
Willing to abstain from sexual intercourse for the required period after each biopsy collection
Exclusion Criteria:
General
-
Weight greater than 115 kg
-
Blood products received within 120 days before first study product administration unless eligibility for earlier enrollment is determined by the HVTN 128 PSRT
-
Investigational research agents received within 30 days before first study product administration
-
Intent to participate in another study of an investigational research agent or any other study that requires non-HVTN HIV antibody testing during the planned duration of the study
-
Pregnant or breastfeeding
Vaccines and other Injections
-
HIV vaccine(s) received in a prior HIV vaccine trial. For volunteers who have received control/placebo in an HIV vaccine trial, the HVTN 128 PSRT will determine eligibility on a case-by-case basis.
-
Previous receipt of humanized or human monoclonal antibodies (mAbs), whether licensed or investigational; the HVTN 128 PSRT will determine eligibility on a case-by-case basis.
-
Previous receipt of monoclonal antibodies against HIV
Immune System
-
Immunosuppressive medications received within 30 days before first infusion (Not exclusionary: [1] corticosteroid nasal spray; [2] inhaled corticosteroids; [3] topical corticosteroids for mild, uncomplicated dermatitis; or [4] a single course of oral/parenteral prednisone or equivalent at doses less than or equal to 20 mg/day and length of therapy less than 14 days)
-
Serious adverse reactions to VRC07-523LS formulation components (sucrose, histidine, and sorbitol; see study protocol for more information), including history of anaphylaxis and related symptoms such as hives, respiratory difficulty, angioedema, and/or abdominal pain.
-
Immunoglobulin received within 90 days before first infusion unless eligibility for earlier enrollment is determined by the HVTN 128 PSRT
-
Autoimmune disease (Not excluded from participation: Volunteer with mild, stable and uncomplicated autoimmune disease that does not require immunosuppressive medication and that, in the judgment of the site investigator, is likely not subject to exacerbation and likely not to complicate Solicited and Unsolicited AE assessments)
-
Immunodeficiency
Clinically significant medical conditions
-
Clinically significant medical condition, physical examination findings, clinically significant abnormal laboratory results, or past medical history with clinically significant implications for current health. A clinically significant condition or process includes but is not limited to:
-
A process that would affect the immune response,
-
A process that would require medication that affects the immune response,
-
Any contraindication to repeated infusions or blood draws, including inability to establish venous access,
-
A condition that requires active medical intervention or monitoring to avert grave danger to the volunteer's health or well-being during the study period,
-
A condition or process (eg, chronic urticaria or recent infusion with evidence of residual inflammation) for which signs or symptoms could be confused with reactions to the study product, or
-
Any condition specifically listed among the exclusion criteria below.
-
Any medical, psychiatric, occupational, or other condition that, in the judgment of the investigator, would interfere with, or serve as a contraindication to, protocol adherence, assessment of safety, Solicited AEs, or a volunteer's ability to give informed consent
-
Psychiatric condition that precludes compliance with the protocol. Specifically excluded are persons with psychoses within the past 3 years, ongoing risk for suicide, or history of suicide attempt or gesture within the past 3 years.
-
Current anti-tuberculosis (TB) therapy
-
Asthma other than mild, well-controlled asthma. (Symptoms of asthma severity as defined in the most recent National Asthma Education and Prevention Program (NAEPP)
Expert Panel report). Exclude a volunteer who:
-
Uses a short-acting rescue inhaler (typically a beta 2 agonist) daily, or
-
Uses moderate/high dose inhaled corticosteroids, or
-
In the past year has either of the following:
-
Greater than 1 exacerbation of symptoms treated with oral/parenteral corticosteroids;
-
Needed emergency care, urgent care, hospitalization, or intubation for asthma.
-
Diabetes mellitus type 1 or type 2. (Not excluded: type 2 cases controlled with diet alone or a history of isolated gestational diabetes.)
-
Hypertension:
-
If a person has been found to have elevated blood pressure or hypertension during screening or previously, exclude for blood pressure that is not well controlled. Well-controlled blood pressure is defined as consistently less than or equal to 140 mm Hg systolic and less than or equal to 90 mm Hg diastolic, with or without medication, with only isolated, brief instances of higher readings, which must be less than or equal to 150 mm Hg systolic and less than or equal to 100 mm Hg diastolic. For these volunteers, blood pressure must be less than or equal to 140 mm Hg systolic and less than or equal to 90 mm Hg diastolic at enrollment.
-
If a person has NOT been found to have elevated blood pressure or hypertension during screening or previously, exclude for systolic blood pressure greater than or equal to 150 mm Hg at enrollment or diastolic blood pressure greater than or equal to 100 mm Hg at enrollment.
-
Bleeding disorder diagnosed by a doctor (eg, factor deficiency, coagulopathy, or platelet disorder requiring special precautions)
-
Malignancy (Not excluded from participation: Volunteer who has had malignancy excised surgically and who, in the investigator's estimation, has a reasonable assurance of sustained cure, or who is unlikely to experience recurrence of malignancy during the period of the study)
-
Seizure disorder: History of seizure(s) within past three years. Also exclude if volunteer has used medications in order to prevent or treat seizure(s) at any time within the past 3 years
-
Asplenia: any condition resulting in the absence of a functional spleen
-
History of hereditary angioedema, acquired angioedema, or idiopathic angioedema.
Mucosal Specimen Collection
-
A rectal condition (for rectal biopsies), such as an active infection or inflammation of the colorectal area (eg, an HSV-2 outbreak or inflamed hemorrhoids or colitis/diarrhea), internal hemorrhoids, or any other condition noted during screening rectal exam via anoscope or in medical history that in the opinion of the clinician represents a contraindication to mucosal sampling.
-
For those who were assigned female sex at birth (for vaginal and cervical biopsies), any condition noted during pelvic exam via speculum or in medical history that in the opinion of the clinician represents a contraindication to mucosal sampling (eg, bacterial vaginosis).
-
An active genital tract condition, such as an active infection or inflammation of the genital tract (eg, genital sores or ulcers, penile or abnormal vaginal discharge, genital warts that are symptomatic or requiring treatment) or any other condition that in the opinion of the clinician represents a contraindication to mucosal sampling.
-
Hysterectomy or bilateral oophorectomy
-
Menopause
-
Current use of anticoagulants
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Brigham and Women's Hospital Vaccine CRS (BWH VCRS) | Boston | Massachusetts | United States | 02115-6110 |
| 2 | Seattle Vaccine and Prevention CRS | Seattle | Washington | United States | 98109-1024 |
Sponsors and Collaborators
- National Institute of Allergy and Infectious Diseases (NIAID)
Investigators
- Study Chair: Stephen Walsh, Brigham and Women's Hospital
- Study Chair: Maria Lemos, Fred Hutch
Study Documents (Full-Text)
More Information
Publications
None provided.- HVTN 128
- 38523
Study Results
Participant Flow
| Recruitment Details | |
|---|---|
| Pre-assignment Detail |
| Arm/Group Title | Group 1: Vaccine | Group 2: Vaccine | Group 3: Pre-treatment |
|---|---|---|---|
| Arm/Group Description | VRC07-523LS (VRC-HIVMAB075-00-AB) 10 mg/kg to be administered IV at weeks 0, 16, and 32 | VRC07-523LS (VRC-HIVMAB075-00-AB) 30 mg/kg to be administered IV at weeks 0, 16, and 32 | Biopsy collected but was not randomized to any treatment group |
| Period Title: Overall Study | |||
| STARTED | 11 | 13 | 4 |
| Safety Population | 11 | 13 | 4 |
| COMPLETED | 9 | 13 | 0 |
| NOT COMPLETED | 2 | 0 | 4 |
Baseline Characteristics
| Arm/Group Title | Group 1: Vaccine | Group 2: Vaccine | Group 3: Pre-treatment | Total |
|---|---|---|---|---|
| Arm/Group Description | VRC07-523LS (VRC-HIVMAB075-00-AB) 10 mg/kg to be administered IV at weeks 0, 16, and 32 | VRC07-523LS (VRC-HIVMAB075-00-AB) 30 mg/kg to be administered IV at weeks 0, 16, and 32 | Biopsy collected but was not randomized to any treatment group | Total of all reporting groups |
| Overall Participants | 11 | 13 | 4 | 28 |
| Age (years) [Median (Full Range) ] | ||||
| Median (Full Range) [years] |
28
|
26
|
22
|
26
|
| Age, Customized (Count of Participants) | ||||
| Less than 18 years |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| 18 - 20 years |
0
0%
|
3
23.1%
|
2
50%
|
5
17.9%
|
| 21 - 30 years |
6
54.5%
|
6
46.2%
|
2
50%
|
14
50%
|
| 31 - 40 years |
4
36.4%
|
1
7.7%
|
0
0%
|
5
17.9%
|
| 41 - 50 years |
1
9.1%
|
3
23.1%
|
0
0%
|
4
14.3%
|
| Above 50 years |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Unknown or Not Reported |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Sex: Female, Male (Count of Participants) | ||||
| Female |
6
54.5%
|
6
46.2%
|
1
25%
|
13
46.4%
|
| Male |
5
45.5%
|
7
53.8%
|
3
75%
|
15
53.6%
|
| Ethnicity (NIH/OMB) (Count of Participants) | ||||
| Hispanic or Latino |
2
18.2%
|
0
0%
|
1
25%
|
3
10.7%
|
| Not Hispanic or Latino |
9
81.8%
|
13
100%
|
3
75%
|
25
89.3%
|
| Unknown or Not Reported |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Race (NIH/OMB) (Count of Participants) | ||||
| American Indian or Alaska Native |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Asian |
0
0%
|
3
23.1%
|
0
0%
|
3
10.7%
|
| Native Hawaiian or Other Pacific Islander |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Black or African American |
1
9.1%
|
2
15.4%
|
1
25%
|
4
14.3%
|
| White |
10
90.9%
|
8
61.5%
|
3
75%
|
21
75%
|
| More than one race |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Unknown or Not Reported |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Region of Enrollment (Count of Participants) | ||||
| USA |
11
100%
|
13
100%
|
4
100%
|
28
100%
|
Outcome Measures
| Title | Number of Participants Reporting Local Reactogenicity Signs and Symptoms |
|---|---|
| Description | Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1, July 2017. The maximum grade observed for each symptom over the time frame is presented. |
| Time Frame | Measured through 3 days after each infusion at weeks 0, 16 and 32 |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Group 1: Vaccine | Group 2: Vaccine |
|---|---|---|
| Arm/Group Description | VRC07-523LS (VRC-HIVMAB075-00-AB) 10 mg/kg to be administered IV at weeks 0, 16, and 32 | VRC07-523LS (VRC-HIVMAB075-00-AB) 30 mg/kg to be administered IV at weeks 0, 16, and 32 |
| Measure Participants | 11 | 13 |
| None |
5
45.5%
|
10
76.9%
|
| Mild |
6
54.5%
|
3
23.1%
|
| Moderate |
0
0%
|
0
0%
|
| Severe |
0
0%
|
0
0%
|
| Potentially Life-threatening |
0
0%
|
0
0%
|
| None |
10
90.9%
|
12
92.3%
|
| Mild |
1
9.1%
|
1
7.7%
|
| Moderate |
0
0%
|
0
0%
|
| Severe |
0
0%
|
0
0%
|
| Potentially Life-threatening |
0
0%
|
0
0%
|
| None |
11
100%
|
12
92.3%
|
| Mild |
0
0%
|
1
7.7%
|
| Moderate |
0
0%
|
0
0%
|
| Severe |
0
0%
|
0
0%
|
| Potentially Life-threatening |
0
0%
|
0
0%
|
| None |
10
90.9%
|
11
84.6%
|
| Mild |
1
9.1%
|
2
15.4%
|
| Moderate |
0
0%
|
0
0%
|
| Severe |
0
0%
|
0
0%
|
| Potentially Life-threatening |
0
0%
|
0
0%
|
| Title | Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms |
|---|---|
| Description | Graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1, July 2017. The maximum grade observed for each symptom over the time frame is presented |
| Time Frame | Measured through 3 days after each infusion at weeks 0, 16 and 32 |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Group 1: Vaccine | Group 2: Vaccine |
|---|---|---|
| Arm/Group Description | VRC07-523LS (VRC-HIVMAB075-00-AB) 10 mg/kg to be administered IV at weeks 0, 16, and 32 | VRC07-523LS (VRC-HIVMAB075-00-AB) 30 mg/kg to be administered IV at weeks 0, 16, and 32 |
| Measure Participants | 11 | 13 |
| None |
3
27.3%
|
4
30.8%
|
| Mild |
6
54.5%
|
5
38.5%
|
| Moderate |
2
18.2%
|
3
23.1%
|
| Severe |
0
0%
|
1
7.7%
|
| Potentially Life-threatening |
0
0%
|
0
0%
|
| None |
8
72.7%
|
8
61.5%
|
| Mild |
3
27.3%
|
3
23.1%
|
| Moderate |
0
0%
|
1
7.7%
|
| Severe |
0
0%
|
1
7.7%
|
| Potentially Life-threatening |
0
0%
|
0
0%
|
| None |
3
27.3%
|
6
46.2%
|
| Mild |
5
45.5%
|
5
38.5%
|
| Moderate |
3
27.3%
|
2
15.4%
|
| Severe |
0
0%
|
0
0%
|
| Potentially Life-threatening |
0
0%
|
0
0%
|
| None |
6
54.5%
|
10
76.9%
|
| Mild |
5
45.5%
|
3
23.1%
|
| Moderate |
0
0%
|
0
0%
|
| Severe |
0
0%
|
0
0%
|
| Potentially Life-threatening |
0
0%
|
0
0%
|
| None |
9
81.8%
|
7
53.8%
|
| Mild |
1
9.1%
|
3
23.1%
|
| Moderate |
1
9.1%
|
1
7.7%
|
| Severe |
0
0%
|
2
15.4%
|
| Potentially Life-threatening |
0
0%
|
0
0%
|
| None |
10
90.9%
|
11
84.6%
|
| Mild |
1
9.1%
|
1
7.7%
|
| Moderate |
0
0%
|
0
0%
|
| Severe |
0
0%
|
1
7.7%
|
| Potentially Life-threatening |
0
0%
|
0
0%
|
| None |
8
72.7%
|
12
92.3%
|
| Mild |
3
27.3%
|
1
7.7%
|
| Moderate |
0
0%
|
0
0%
|
| Severe |
0
0%
|
0
0%
|
| Potentially Life-threatening |
0
0%
|
0
0%
|
| None |
11
100%
|
12
92.3%
|
| Mild |
0
0%
|
1
7.7%
|
| Moderate |
0
0%
|
0
0%
|
| Severe |
0
0%
|
0
0%
|
| Potentially Life-threatening |
0
0%
|
0
0%
|
| None |
11
100%
|
13
100%
|
| Mild |
0
0%
|
0
0%
|
| Moderate |
0
0%
|
0
0%
|
| Severe |
0
0%
|
0
0%
|
| Potentially Life-threatening |
0
0%
|
0
0%
|
| None |
10
90.9%
|
13
100%
|
| Mild |
1
9.1%
|
0
0%
|
| Moderate |
0
0%
|
0
0%
|
| Severe |
0
0%
|
0
0%
|
| Potentially Life-threatening |
0
0%
|
0
0%
|
| None |
11
100%
|
12
92.3%
|
| Mild |
0
0%
|
0
0%
|
| Moderate |
0
0%
|
1
7.7%
|
| Severe |
0
0%
|
0
0%
|
| Potentially Life-threatening |
0
0%
|
0
0%
|
| None |
10
90.9%
|
13
100%
|
| Mild |
1
9.1%
|
0
0%
|
| Moderate |
0
0%
|
0
0%
|
| Severe |
0
0%
|
0
0%
|
| Potentially Life-threatening |
0
0%
|
0
0%
|
| None |
1
9.1%
|
2
15.4%
|
| Mild |
5
45.5%
|
7
53.8%
|
| Moderate |
5
45.5%
|
2
15.4%
|
| Severe |
0
0%
|
2
15.4%
|
| Potentially Life-threatening |
0
0%
|
0
0%
|
| None |
10
90.9%
|
11
84.6%
|
| Mild |
1
9.1%
|
0
0%
|
| Moderate |
0
0%
|
2
15.4%
|
| Severe |
0
0%
|
0
0%
|
| Potentially Life-threatening |
0
0%
|
0
0%
|
| Title | Chemistry and Hematology Laboratory Measures - Alanine Aminotransferase (ALT) in U/L |
|---|---|
| Description | For each local laboratory measure, summary statistics were presented by treatment group and timepoint for the overall population. |
| Time Frame | Measured during screening, visit 4(day 14), 6 (day 126) and 8 (day 238) |
Outcome Measure Data
| Analysis Population Description |
|---|
| Samples were missing for follow-up visits due to miss visits or discontinuing study product. |
| Arm/Group Title | Group 1: Vaccine | Group 2: Vaccine |
|---|---|---|
| Arm/Group Description | VRC07-523LS (VRC-HIVMAB075-00-AB) 10 mg/kg to be administered IV at weeks 0, 16, and 32 | VRC07-523LS (VRC-HIVMAB075-00-AB) 30 mg/kg to be administered IV at weeks 0, 16, and 32 |
| Measure Participants | 11 | 13 |
| ALT (SGPT) (U/L)- Screening |
19.0
|
16.0
|
| ALT (SGPT) (U/L)-Day 14 |
14.0
|
16.0
|
| ALT (SGPT) (U/L)-Day 126 |
22.0
|
17.0
|
| ALT (SGPT) (U/L)-Day 238 |
16.0
|
14.0
|
| Title | Chemistry and Hematology Laboratory Measures- Hemoglobin and Creatinine (g/dl) |
|---|---|
| Description | For each local laboratory measure-Hemoglobin and Creatinine (g/dl), summary statistics were presented by treatment group and time point for the overall population. |
| Time Frame | Measured during screening, Day 14, 126, 238 |
Outcome Measure Data
| Analysis Population Description |
|---|
| Samples were missing for follow-up visits due to miss visits or discontinuing study product. |
| Arm/Group Title | Group 1: Vaccine | Group 2: Vaccine |
|---|---|---|
| Arm/Group Description | VRC07-523LS (VRC-HIVMAB075-00-AB) 10 mg/kg to be administered IV at weeks 0, 16, and 32 | VRC07-523LS (VRC-HIVMAB075-00-AB) 30 mg/kg to be administered IV at weeks 0, 16, and 32 |
| Measure Participants | 11 | 13 |
| Hemoglobin (g/dL)- Screening |
14.3
|
13.9
|
| Hemoglobin (g/dL)-Day 14 |
13.4
|
13.2
|
| Hemoglobin (g/dL)-Day 126 |
13.9
|
14.0
|
| Hemoglobin (g/dL)-Day 238 |
13.9
|
13.2
|
| Creatinine (g/dL)- Screening |
.00076
|
.00078
|
| Creatinine (g/dL)-Day 14 |
.00082
|
.00081
|
| Creatinine (g/dL)-Day 126 |
.00077
|
.00081
|
| Creatinine (g/dL)-Day 238 |
.00070
|
.00085
|
| Title | Chemistry and Hematology Laboratory Measures- Lymphocyte Count, Neutrophil Count, Platelets, White Blood Cells (WBC) |
|---|---|
| Description | For each local laboratory measure lymphocyte count, neutrophil count, platelets, white blood cells (WBC) in 1000/ cubic mm summary statistics were presented by treatment group and time point |
| Time Frame | Measured during screening, Day 14, 126, 238 |
Outcome Measure Data
| Analysis Population Description |
|---|
| Samples were missing for follow-up visits due to miss visits or discontinuing study product. |
| Arm/Group Title | Group 1: Vaccine | Group 2: Vaccine |
|---|---|---|
| Arm/Group Description | VRC07-523LS (VRC-HIVMAB075-00-AB) 10 mg/kg to be administered IV at weeks 0, 16, and 32 | VRC07-523LS (VRC-HIVMAB075-00-AB) 30 mg/kg to be administered IV at weeks 0, 16, and 32 |
| Measure Participants | 11 | 13 |
| WBC (1000 cells/cubic mm)- Screening |
8.03
|
7.12
|
| WBC (1000 cells/cubic mm)-Day 14 |
6.22
|
7.12
|
| WBC (1000 cells/cubic mm)-Day 126 |
7.63
|
5.55
|
| WBC (1000 cells/cubic mm)-Day 238 |
8.02
|
5.22
|
| Neutrophils (1000 cells/cubic mm)- Screening |
4.74
|
3.45
|
| Neutrophils (1000 cells/cubic mm)-Day 14 |
3.65
|
3.90
|
| Neutrophils (1000 cells/cubic mm)-Day 126 |
4.98
|
3.19
|
| Neutrophils (1000 cells/cubic mm)-Day 238 |
4.75
|
3.10
|
| Lymphocytes (1000 cells/cubic mm)- Screening |
2.30
|
2.28
|
| Lymphocytes (1000 cells/cubic mm)-Day 14 |
1.91
|
1.82
|
| Lymphocytes (1000 cells/cubic mm)-Day 126 |
1.72
|
1.71
|
| Lymphocytes (1000 cells/cubic mm)-Day 238 |
2.04
|
1.64
|
| Platelets (1000 cells/cubic mm)- Screening |
260
|
249
|
| Platelets (1000 cells/cubic mm)-Day 14 |
243
|
225
|
| Platelets (1000 cells/cubic mm)-Day 126 |
247
|
253
|
| Platelets (1000 cells/cubic mm)-Day 238 |
239
|
264
|
| Title | Chemistry and Hematology Laboratory Measures |
|---|---|
| Description | Counts of lab grade >1 for ALT, creatine, hemoglobin, lymphocyte count, neutrophil, platelets, white blood cells |
| Time Frame | Measured during screening, Day 14, 126, 238 |
Outcome Measure Data
| Analysis Population Description |
|---|
| Samples were missing for follow-up visits due to miss visits or discontinuing study product. |
| Arm/Group Title | Group 1: Vaccine | Group 2: Vaccine |
|---|---|---|
| Arm/Group Description | VRC07-523LS (VRC-HIVMAB075-00-AB) 10 mg/kg to be administered IV at weeks 0, 16, and 32 | VRC07-523LS (VRC-HIVMAB075-00-AB) 30 mg/kg to be administered IV at weeks 0, 16, and 32 |
| Measure Participants | 11 | 13 |
| WBC (1000 cells/cubic mm)- Screening |
0
0%
|
0
0%
|
| WBC (1000 cells/cubic mm)-Day 14 |
0
0%
|
0
0%
|
| WBC (1000 cells/cubic mm)-Day 126 |
0
0%
|
0
0%
|
| WBC (1000 cells/cubic mm)-Day 238 |
0
0%
|
0
0%
|
| Neutrophils (1000 cells/cubic mm)- Screening |
0
0%
|
0
0%
|
| Neutrophils (1000 cells/cubic mm)-Day 14 |
0
0%
|
0
0%
|
| Neutrophils (1000 cells/cubic mm)-Day 126 |
0
0%
|
0
0%
|
| Neutrophils (1000 cells/cubic mm)-Day 238 |
0
0%
|
0
0%
|
| Hemoglobin (g/dL)- Screening |
0
0%
|
0
0%
|
| Hemoglobin (g/dL)-Day 14 |
0
0%
|
0
0%
|
| Hemoglobin (g/dL)-Day 126 |
0
0%
|
0
0%
|
| Hemoglobin (g/dL)-Day 238 |
0
0%
|
0
0%
|
| Lymphocytes (1000 cells/cubic mm)- Screening |
0
0%
|
0
0%
|
| Lymphocytes (1000 cells/cubic mm)-Day 14 |
0
0%
|
0
0%
|
| Lymphocytes (1000 cells/cubic mm)-Day 126 |
0
0%
|
0
0%
|
| Lymphocytes (1000 cells/cubic mm)-Day 238 |
0
0%
|
0
0%
|
| Platelets (1000 cells/cubic mm)- Screening |
0
0%
|
0
0%
|
| Platelets (1000 cells/cubic mm)-Day 14 |
0
0%
|
0
0%
|
| Platelets (1000 cells/cubic mm)-Day 126 |
0
0%
|
0
0%
|
| Platelets (1000 cells/cubic mm)-Day 238 |
0
0%
|
0
0%
|
| ALT (SGPT) (U/L)- Screening |
0
0%
|
0
0%
|
| ALT (SGPT) (U/L)-Day 14 |
0
0%
|
0
0%
|
| ALT (SGPT) (U/L)-Day 126 |
0
0%
|
0
0%
|
| ALT (SGPT) (U/L)-Day 238 |
0
0%
|
0
0%
|
| Creatinine (g/dL)- Screening |
0
0%
|
0
0%
|
| Creatinine (g/dL)-Day 14 |
0
0%
|
0
0%
|
| Creatinine (g/dL)-Day 126 |
1
9.1%
|
0
0%
|
| Creatinine (g/dL)-Day 238 |
0
0%
|
0
0%
|
| Title | Number of Participants Reporting Adverse Events (AEs) |
|---|---|
| Description | Participants Max severity reported per participant over visit. |
| Time Frame | Enrollment through week 48 |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Group 1: Vaccine | Group 2: Vaccine |
|---|---|---|
| Arm/Group Description | VRC07-523LS (VRC-HIVMAB075-00-AB) 10 mg/kg to be administered IV at weeks 0, 16, and 32 | VRC07-523LS (VRC-HIVMAB075-00-AB) 30 mg/kg to be administered IV at weeks 0, 16, and 32 |
| Measure Participants | 11 | 13 |
| Mild |
1
9.1%
|
4
30.8%
|
| Moderate |
9
81.8%
|
6
46.2%
|
| Severe |
0
0%
|
2
15.4%
|
| Potentially life-threatening |
0
0%
|
0
0%
|
| No AE reported |
1
9.1%
|
1
7.7%
|
| Title | Number of Participants With Early Discontinuation of Vaccinations and Reason for Discontinuation |
|---|---|
| Description | The number (percentage) of participants with early discontinuation of vaccinations and reason for discontinuation was summarized by arm |
| Time Frame | Enrollment through last scheduled dose at week 32 |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Group 1: Vaccine | Group 2: Vaccine |
|---|---|---|
| Arm/Group Description | VRC07-523LS (VRC-HIVMAB075-00-AB) 10 mg/kg to be administered IV at weeks 0, 16, and 32 | VRC07-523LS (VRC-HIVMAB075-00-AB) 30 mg/kg to be administered IV at weeks 0, 16, and 32 |
| Measure Participants | 11 | 13 |
| Clinical event (not reacto, HIV, death) |
0
0%
|
2
15.4%
|
| Subject unable to attend clinic visits |
1
9.1%
|
0
0%
|
| Did not discontinue SPA |
10
90.9%
|
11
84.6%
|
Adverse Events
| Time Frame | Enrollment through week 48 | |||||
|---|---|---|---|---|---|---|
| Adverse Event Reporting Description | Number of Participants Reporting Adverse Events (AEs) | |||||
| Arm/Group Title | Group 1: Vaccine | Group 2: Vaccine | Group 3: Pre-treatment | |||
| Arm/Group Description | VRC07-523LS (VRC-HIVMAB075-00-AB) 10 mg/kg to be administered IV at weeks 0, 16, and 32 | VRC07-523LS (VRC-HIVMAB075-00-AB) 30 mg/kg to be administered IV at weeks 0, 16, and 32 | Biopsy collected but was not randomized to any treatment group | |||
All Cause Mortality |
||||||
| Group 1: Vaccine | Group 2: Vaccine | Group 3: Pre-treatment | ||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 0/11 (0%) | 0/13 (0%) | 0/4 (0%) | |||
Serious Adverse Events |
||||||
| Group 1: Vaccine | Group 2: Vaccine | Group 3: Pre-treatment | ||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 0/11 (0%) | 0/13 (0%) | 0/4 (0%) | |||
Other (Not Including Serious) Adverse Events |
||||||
| Group 1: Vaccine | Group 2: Vaccine | Group 3: Pre-treatment | ||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 10/11 (90.9%) | 12/13 (92.3%) | 0/4 (0%) | |||
| Ear and labyrinth disorders | ||||||
| Any Event in SOC | 1/11 (9.1%) | 1 | 0/13 (0%) | 0 | 0/4 (0%) | 0 |
| Vertigo positional | 1/11 (9.1%) | 1 | 0/13 (0%) | 0 | 0/4 (0%) | 0 |
| Eye disorders | ||||||
| Any Event in SOC | 0/11 (0%) | 0 | 1/13 (7.7%) | 1 | 0/4 (0%) | 0 |
| Chalazion | 0/11 (0%) | 0 | 1/13 (7.7%) | 1 | 0/4 (0%) | 0 |
| Gastrointestinal disorders | ||||||
| Any Event in SOC | 4/11 (36.4%) | 4 | 0/13 (0%) | 0 | 0/4 (0%) | 0 |
| Diarrhoea | 2/11 (18.2%) | 2 | 0/13 (0%) | 0 | 0/4 (0%) | 0 |
| Dyspepsia | 1/11 (9.1%) | 1 | 0/13 (0%) | 0 | 0/4 (0%) | 0 |
| Oral pruritus | 1/11 (9.1%) | 1 | 0/13 (0%) | 0 | 0/4 (0%) | 0 |
| General disorders | ||||||
| Any Event in SOC | 2/11 (18.2%) | 2 | 1/13 (7.7%) | 1 | 0/4 (0%) | 0 |
| Feeling cold | 1/11 (9.1%) | 1 | 0/13 (0%) | 0 | 0/4 (0%) | 0 |
| Influenza like illness | 1/11 (9.1%) | 1 | 1/13 (7.7%) | 1 | 0/4 (0%) | 0 |
| Infections and infestations | ||||||
| Any Event in SOC | 9/11 (81.8%) | 24 | 5/13 (38.5%) | 5 | 0/4 (0%) | 0 |
| Bacterial vaginosis | 3/11 (27.3%) | 4 | 0/13 (0%) | 0 | 0/4 (0%) | 0 |
| Bronchitis | 1/11 (9.1%) | 1 | 0/13 (0%) | 0 | 0/4 (0%) | 0 |
| Gastroenteritis | 1/11 (9.1%) | 1 | 0/13 (0%) | 0 | 0/4 (0%) | 0 |
| Hordeolum | 1/11 (9.1%) | 1 | 0/13 (0%) | 0 | 0/4 (0%) | 0 |
| Molluscum contagiosum | 0/11 (0%) | 0 | 1/13 (7.7%) | 1 | 0/4 (0%) | 0 |
| Otitis externa | 1/11 (9.1%) | 1 | 0/13 (0%) | 0 | 0/4 (0%) | 0 |
| Upper respiratory tract infection | 8/11 (72.7%) | 11 | 3/13 (23.1%) | 3 | 0/4 (0%) | 0 |
| Viral infection | 1/11 (9.1%) | 1 | 0/13 (0%) | 0 | 0/4 (0%) | 0 |
| Vulvovaginal candidiasis | 0/11 (0%) | 0 | 1/13 (7.7%) | 1 | 0/4 (0%) | 0 |
| Vulvovaginal mycotic infection | 2/11 (18.2%) | 4 | 0/13 (0%) | 0 | 0/4 (0%) | 0 |
| Injury, poisoning and procedural complications | ||||||
| Any Event in SOC | 3/11 (27.3%) | 4 | 7/13 (53.8%) | 7 | 0/4 (0%) | 0 |
| Infusion related reaction | 2/11 (18.2%) | 3 | 5/13 (38.5%) | 5 | 0/4 (0%) | 0 |
| Muscle injury | 1/11 (9.1%) | 1 | 0/13 (0%) | 0 | 0/4 (0%) | 0 |
| Post procedural swelling | 0/11 (0%) | 0 | 1/13 (7.7%) | 1 | 0/4 (0%) | 0 |
| Skin laceration | 0/11 (0%) | 0 | 1/13 (7.7%) | 1 | 0/4 (0%) | 0 |
| Investigations | ||||||
| Any Event in SOC | 3/11 (27.3%) | 6 | 2/13 (15.4%) | 2 | 0/4 (0%) | 0 |
| Alanine aminotransferase increased | 1/11 (9.1%) | 1 | 0/13 (0%) | 0 | 0/4 (0%) | 0 |
| Blood bilirubin increased | 1/11 (9.1%) | 1 | 0/13 (0%) | 0 | 0/4 (0%) | 0 |
| Blood creatinine increased | 2/11 (18.2%) | 2 | 0/13 (0%) | 0 | 0/4 (0%) | 0 |
| Blood pressure increased | 1/11 (9.1%) | 1 | 0/13 (0%) | 0 | 0/4 (0%) | 0 |
| Haemoglobin decreased | 0/11 (0%) | 0 | 1/13 (7.7%) | 1 | 0/4 (0%) | 0 |
| Lymphocyte count decreased | 0/11 (0%) | 0 | 1/13 (7.7%) | 1 | 0/4 (0%) | 0 |
| Smear cervix abnormal | 1/11 (9.1%) | 1 | 0/13 (0%) | 0 | 0/4 (0%) | 0 |
| Metabolism and nutrition disorders | ||||||
| Any Event in SOC | 1/11 (9.1%) | 1 | 0/13 (0%) | 0 | 0/4 (0%) | 0 |
| Dehydration | 1/11 (9.1%) | 1 | 0/13 (0%) | 0 | 0/4 (0%) | 0 |
| Musculoskeletal and connective tissue disorders | ||||||
| Any Event in SOC | 3/11 (27.3%) | 3 | 2/13 (15.4%) | 2 | 0/4 (0%) | 0 |
| Back pain | 1/11 (9.1%) | 1 | 0/13 (0%) | 0 | 0/4 (0%) | 0 |
| Coccydynia | 1/11 (9.1%) | 1 | 0/13 (0%) | 0 | 0/4 (0%) | 0 |
| Myalgia | 1/11 (9.1%) | 1 | 0/13 (0%) | 0 | 0/4 (0%) | 0 |
| Neck pain | 0/11 (0%) | 0 | 1/13 (7.7%) | 1 | 0/4 (0%) | 0 |
| Tendonitis | 0/11 (0%) | 0 | 1/13 (7.7%) | 1 | 0/4 (0%) | 0 |
| Nervous system disorders | ||||||
| Any Event in SOC | 3/11 (27.3%) | 3 | 4/13 (30.8%) | 4 | 0/4 (0%) | 0 |
| Disturbance in attention | 1/11 (9.1%) | 1 | 0/13 (0%) | 0 | 0/4 (0%) | 0 |
| Dizziness postural | 1/11 (9.1%) | 1 | 0/13 (0%) | 0 | 0/4 (0%) | 0 |
| Headache | 1/11 (9.1%) | 1 | 1/13 (7.7%) | 1 | 0/4 (0%) | 0 |
| Migraine | 0/11 (0%) | 0 | 1/13 (7.7%) | 1 | 0/4 (0%) | 0 |
| Presyncope | 0/11 (0%) | 0 | 1/13 (7.7%) | 1 | 0/4 (0%) | 0 |
| Syncope | 0/11 (0%) | 0 | 1/13 (7.7%) | 1 | 0/4 (0%) | 0 |
| Psychiatric disorders | ||||||
| Any Event in SOC | 0/11 (0%) | 0 | 1/13 (7.7%) | 1 | 0/4 (0%) | 0 |
| Depression | 0/11 (0%) | 0 | 1/13 (7.7%) | 1 | 0/4 (0%) | 0 |
| Renal and urinary disorders | ||||||
| Any Event in SOC | 1/11 (9.1%) | 1 | 1/13 (7.7%) | 1 | 0/4 (0%) | 0 |
| Dysuria | 1/11 (9.1%) | 1 | 0/13 (0%) | 0 | 0/4 (0%) | 0 |
| Haematuria | 0/11 (0%) | 0 | 1/13 (7.7%) | 1 | 0/4 (0%) | 0 |
| Respiratory, thoracic and mediastinal disorders | ||||||
| Any Event in SOC | 2/11 (18.2%) | 2 | 0/13 (0%) | 0 | 0/4 (0%) | 0 |
| Oropharyngeal pain | 1/11 (9.1%) | 1 | 0/13 (0%) | 0 | 0/4 (0%) | 0 |
| Sinus congestion | 1/11 (9.1%) | 1 | 0/13 (0%) | 0 | 0/4 (0%) | 0 |
| Skin and subcutaneous tissue disorders | ||||||
| Any Event in SOC | 2/11 (18.2%) | 2 | 1/13 (7.7%) | 1 | 0/4 (0%) | 0 |
| Dermatitis contact | 1/11 (9.1%) | 1 | 0/13 (0%) | 0 | 0/4 (0%) | 0 |
| Erythema | 1/11 (9.1%) | 1 | 0/13 (0%) | 0 | 0/4 (0%) | 0 |
| Pruritus | 0/11 (0%) | 0 | 1/13 (7.7%) | 1 | 0/4 (0%) | 0 |
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
| Name/Title | Jessica Andriesen, PhD, Associate Director of HVTN SDMC Operations |
|---|---|
| Organization | Fred Hutchinson Cancer Research Center |
| Phone | 206-667-5812 |
| jandries@fredhutch.org |
- HVTN 128
- 38523